Literature DB >> 17958546

Platelet and red blood cell phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells.

Rukhsana Aslam1, Michael Kim, Edwin R Speck, Arjuna Contram Seetanah, Steven Molinski, John Freedman, John W Semple.   

Abstract

BACKGROUND: Anti-D treatment is effective in increasing platelet (PLT) counts in patients with autoimmune thrombocytopenic purpura (AITP); however, the exact mechanism of action is unknown. Previous results have suggested that anti-D-coated red blood cells (RBCs) affect reticuloendothelial system phagocytosis by stimulating agents (e.g., reactive oxygen species) that alter signaling pathways within the phagocyte. To address this, a flow cytometric assay was used to compare the kinetics and signaling pathways responsible for opsonized PLT and RBC phagocytosis. STUDY DESIGN AND METHODS: Human RBCs or PLTs were labeled with the fluorescent dye CM-Green, opsonized with Rh immune globulin or anti-MHC, respectively, and incubated with THP-1 monocytes with or without signal transduction inhibitors and intracellular fluorescence was analyzed.
RESULTS: Compared with opsonized PLTs, phagocytosis of opsonized RBCs was significantly slower (p<0.0001) and, within 2 hours, induced a state of phagocytic refractoriness; resting the mononuclear cells (MNCs) for up to 24 hours did not rescue their ability to further mediate PLT phagocytosis. Inhibitors of phosphatidylinositol 3-kinase (wortmannin, LY294002, myricetin, and quercetin), protein kinase C (staurosporine), and Syk kinase (piceatannol) inhibited both opsonized RBC and opsonized PLT phagocytosis. In contrast, opsonized RBC phagocytosis was significantly (p<0.0001) enhanced by the tyrosine phosphatase inhibitor phenyl arsine oxide, whereas PLT phagocytosis was significantly reduced (p<0.0001). Of interest, phosphatase inhibition during opsonized RBC phagocytosis induced a longer (48 hr) phagocytic refractoriness period in the MNCs.
CONCLUSION: These results suggest that the early kinetics and signaling events related to phosphatase activity regulate how mononuclear phagocytes engulf opsonized RBCs and induce phagocytic refractoriness for further PLT phagocytosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958546     DOI: 10.1111/j.1537-2995.2007.01441.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue.

Authors:  Eugenio D Hottz; Isabel M Medeiros-de-Moraes; Adriana Vieira-de-Abreu; Edson F de Assis; Rogério Vals-de-Souza; Hugo C Castro-Faria-Neto; Andrew S Weyrich; Guy A Zimmerman; Fernando A Bozza; Patrícia T Bozza
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

2.  A numerical analysis model for interpretation of flow cytometric studies of ex vivo phagocytosis.

Authors:  Ted S Strom; Praveen Anur; Amanda Prislovsky
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

Review 3.  Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?

Authors:  Olivier Garraud; Hind Hamzeh-Cognasse; Bruno Pozzetto; Jean-Marc Cavaillon; Fabrice Cognasse
Journal:  Crit Care       Date:  2013-08-27       Impact factor: 9.097

4.  Co-culture of monocytes and zona fasciculata adrenal cells: An in vitro model to study the immune-adrenal cross-talk.

Authors:  Daniel P Fudulu; George Horn; Georgina Hazell; Anne-Marie Lefrançois-Martinez; Antoine Martinez; Gianni D Angelini; Stafford L Lightman; Francesca Spiga
Journal:  Mol Cell Endocrinol       Date:  2021-02-09       Impact factor: 4.102

5.  Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease.

Authors:  Mouli Pal; Weili Bao; Rikang Wang; Yunfeng Liu; Xiuli An; William B Mitchell; Cheryl A Lobo; Caterina Minniti; Patricia A Shi; Deepa Manwani; Karina Yazdanbakhsh; Hui Zhong
Journal:  Blood       Date:  2021-01-14       Impact factor: 25.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.